On April 12, 2023, U.S. pharma giant Pfizer has signed an agreement with China in Shanghai to cooperate on improving “Healthy China 2030” , according to the company. Peng Zhenke, President of Pfizer China, and Liu Yong, President of Sinopharm Holdings Limited, signed the contract on behalf of both parties. Pfizer and China-based Sinopharm Group have teamed up to seek approval for 12 new drugs covering tumor, vaccine, anti-infection and inflammation, and immunity in China through 2025. In 2016, China announced a “Healthy China 2030” initiative for improving the country’s public health services, medical industry and food and drug safety.

According to Brand Value (China) Network, Pfizer CEO Albert Bourla spoke during the China Development Forum in Beijing on March 25, 2023 and he told CNBC News “We are aligned very much with the China ‘Healthy 2030’ [initiative] and we are trying to contribute as much as we can”, however he did not discuss the Paxlovid drug for treating Covid. On March 28, 2023, NHSA (National Healthcare Security Administration) in China issued a notice on Improving the Pricing Mechanism of COVID-19 Therapeutic Drugs and Implementing Classified Management， which does not include Paxlovid in the Chinese public health insurance scheme and makes Paxlovid an out of pocket COVID-19 drug in China after April 1, 2023.

According to Brand Value (China) Network, Paxlovid is a combination of two antiviral medications that are taken together. It works by preventing the COVID-19 virus from making copies of itself in the body. Paxlovid is the first-choice treatment for mild to moderate COVID-19 in people with a higher risk of severe illness. Paxlovid was added to China's National Guidelines for Diagnosis and Treatment of COVID-19 in March 2022. However, Paxlovid is not a miracle drug because the COVID-19 Pandemic is over not only in China but also in the rest of the world.

Pfizer is an American multinational pharmaceutical and biotechnology corporation headquartered in Manhattan, New York City. The year of 2022 was a successful year for Pfizer because Pfizer served as many as 1.2 billion patients worldwide. Pfizer estimated that its revenue in 2022 would be close to US $100 billion, equivalent to 676.8 billion yuan, a year-on-year increase of 23%. Pfizer right now has a nickname called “A money printing machine”. Many people can’t help but asking a question- Why does Pfizer have such an amazing achievement? According to Brand Value (China) Network, that’s because Pfizer has one thing other companies don’t have: a lightening speed to make a world-class product. For example, on March 11, 2020, WHO (World Health Organization) officially declared the COVID-19 Pandemic. On March 17, 2020, Pfizer signed a contract with a German company in just one day and the race for a vaccine was under way. 9 Months later, on November 15, 2020, Pfizer released a messenger RNA (mRNA) vaccine, with 90% efficacy for the prevention of COVID-19. In August , 2021, the Pfizer-BioNTech vaccine (brand name: Comirnaty) was granted full Food and Drug Administration (FDA) approval for people ages 16 and older. In 2021, 3 billion doses were made and its net sales reached RMB 36.9 billion.  For another example, on November 4, 2021, Great Britain approved Merck’s molnupiravir, a potentially game-changing COVID-19 antiviral pill. Just one day later, on November 5, 2022, Pfizer announced its Paxlovid (an antiviral pill ) could slash risk of severe COVID-19 by 89%.  After the announcement, the stock price of Pfizer (NYSE: PFE) surged 11% in a single day and its CEO called that’s a proud day for Pfizer. According to Brand Value (China) Network, Pfizer was one of the biggest winners during the COVID-19 Pandemic because Pfizer, an American Pharmaceutical giant, has the ability to integrate talents, technology and capital in an amazing speed to make a new product. Right now, Pfizer is planning to develop 19 new products in 18 months, which is similar to the COVID-19 vaccine project called “Project Lightspeed”.

On the ranking of “The 3rd Daguan· Keweiwei World Brand Value Top 900” released on March 18, 2023, Pfizer’s brand value was 701.675 billion RMB, ranking the 20th; Merck’s brand value was 251.423 billion RMB, ranking 89th.

www.bvrcn.com 品牌价值（中国）网

作者：杨瑞安